SYK Pathway
SYK inhibition had been shown to inhibit platelet aggregation in heparin-induced thrombocytopenia models, a disease sharing mechanistic features with COVID-19. The SYK pathway was identified as a candidate therapeutic target in COVID-19, b…
1 sources - 3 claims
SYK inhibition had been shown to inhibit platelet aggregation in heparin-induced thrombocytopenia models, a disease sharing mechanistic features with COVID-19. The SYK pathway was identified as a candidate therapeutic target in COVID-19, being activated by C-type lectin receptors, C-type lectin-like receptors, and Fc receptors. SYK inhibition suppresses platelet activation and cytokine release, both of which are critical events in COVID-19 pathogenesis.